In the last trading session, 1.05 million shares of the Precision Biosciences Inc (NASDAQ:DTIL) were traded, and its beta was 1.57. Most recently the company’s share price was $5.52, and it changed around $1.06 or 23.77% from the last close, which brings the market valuation of the company to $57.86M. DTIL currently trades at a discount to its 52-week high of $14.39, offering almost -160.69% off that amount. The share price’s 52-week low was $3.61, which indicates that the current value has risen by an impressive 34.6% since then. We note from Precision Biosciences Inc’s average daily trading volume that its 10-day average is 0.29 million shares, with the 3-month average coming to 153.56K.
Precision Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended DTIL as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Precision Biosciences Inc is expected to report earnings per share of -2.42 for the current quarter.
Precision Biosciences Inc (NASDAQ:DTIL) trade information
Instantly DTIL has showed a green trend with a performance of 23.77% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 5.73 on recent trading dayincreased the stock’s daily price by 3.66%. The company’s shares are currently up 44.88% year-to-date, but still up 19.48% over the last five days. On the other hand, Precision Biosciences Inc (NASDAQ:DTIL) is 9.31% up in the 30-day period. We can see from the shorts that 0.75 million shares have been sold at a short interest cover period of 5.59 day(s).
The consensus price target as assigned by Wall Street analysts is $15.5, which translates to bulls needing to increase their stock price by 64.39% from its current value. Analyst projections state that DTIL is forecast to be at a low of $1 and a high of $30.
Precision Biosciences Inc (DTIL) estimates and forecasts
The year-over-year growth rate is expected to be -74.20%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 5M in revenue for the current quarter. 3 analysts expect Precision Biosciences Inc to make 6.27M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 17.58M and 49.9M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -71.57%. Forecasts for the next quarter put sales growth at -87.44%.
DTIL Dividends
Precision Biosciences Inc’s next quarterly earnings report is expected to be released on 2025-Mar-25.
Precision Biosciences Inc (NASDAQ:DTIL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 18.24% of Precision Biosciences Inc shares, and 38.01% of them are in the hands of institutional investors. The stock currently has a share float of 46.49%. Precision Biosciences Inc stock is held by 69.0 institutions, with TANG CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 8.9473% of the shares, which is about 0.62 million shares worth $6.07 million.
PERCEPTIVE ADVISORS LLC, with 6.119% or 0.43 million shares worth $4.15 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
